Schusterman and Duquesne led the $50m Series B funding round in Ratio Therapeutics.

Schusterman, a family foundation, and Duquesne, an investment firm, led the $50m Series B funding round in Ratio Therapeutics, a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of cancers, with participation from PagsGroup, Bristol Myers Squibb and the Center for Technology Licensing at Cornell University. "This funding advances Ratio's technology platforms and will help launch clinical trials for our FAP-targeted radiotherapeutic which aims to treat a broad array of solid-tumor cancers. We are grateful to our investors for their confidence in our technology," Jack Hoppin, Ratio Chairman and CEO.